A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)

← catalyst calendar

NCT06382987 · readout in 1,230 d

Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.

Phase

—

Status

Recruiting

Study type

Observational

Enrollment

600estimated

Sites

Country

Japan

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-01-22

actual

When the study began enrolling

Primary completion

2029-12-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2029-12-31

estimated

The whole study's end, after follow-up

First posted

2024-04-25

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2024-04-25

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Plaque Psoriasis

Interventions

Drug: Deucravacitinib
Drug: Apremilast

Primary outcomes

what the primary-completion date above is the date OF

Change in percent Body Surface Area (BSA) involved affected by plaque psoriasis from baseline to follow up in participants treated with deucravacitinib.